Partially-blind, Randomized, Parallel Group, Placebo and Active Comparator-controlled Phase I Clinical Trial to Evaluate the Photosensitivity Potential of BI 730357
Latest Information Update: 19 Jul 2023
At a glance
- Drugs BI 730357 (Primary) ; Ciprofloxacin
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
Most Recent Events
- 10 Sep 2020 Status changed from active, no longer recruiting to completed.
- 27 Aug 2020 Status changed from recruiting to active, no longer recruiting.
- 15 Jul 2020 Planned End Date changed from 31 Aug 2020 to 27 Aug 2020.